Activated factor XII type A predicts long-term mortality in patients admitted with chest pain

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 2, 2009, Pages 277-287

  Pönitz, Volker ^a,b   Brugger Andersen T ^a,b   Pritchard, D ^c   Grundt, H ^a,b   Staines, H ^d   Nilsen, D W T ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c Axis Shield Diagnostics Ltd   (United Kingdom)

^d Sigma Statistical Services   (United Kingdom)

Author keywords

Acute coronary syndrome; Chest pain; Factor XIIaA; Myocardial infarction; Prognosis; Risk assessment

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; TRINITROTOLUENE; TROPONIN;

ACUTE CORONARY SYNDROME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SMOKING; ST SEGMENT ELEVATION; SURVIVAL TIME; THORAX PAIN;

AGED; CHEST PAIN; FACTOR XIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVORS;

EID: 59049102969     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03248.x     Document Type: Article

References (40)

1. Wu AHB, Apple FS, Gibler BG, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery disease. Clin Chem 1999; 45: 1104-21.
2. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Eng J Med 1996; 335: 1342-9.
3. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute cardiac chest pain by means of rapid testing for troponin T or troponin I. N Engl J Med 1997; 337: 1648-53.
4. Heeschen C, Hamm CW, Goldman B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficiacy of tirofiban. Prism Study Investigators. Platelet Receptor inhibition in ischemic syndrome management. Lancet 1999; 354: 1757-62.
5. Ohnman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA investigators. N Engl J Med 1996; 335: 1333-41.
6. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease. J Am Coll Cardiol 2006; 48: 1-11.
7. Kaplan AP, Austen KF. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 1971; 133: 696-712.
8. Murano G. The "Hageman" Connection: Interrelationships of blood coagulation, fibrino(geno)lysis, kinin generation, and complement activation. Am J Hematol 1978; 4: 409-17.
9. Kurachi K, Fujikawa K, Davie EW. Mechanism of activation of bovine factor XI by factor XII and factor XIIa. Biochemistry 1980; 19: 1330-8.
10. Radcliffe R, Bangdasarian A, Colman R, Nemerson Y. Activation of bovine factor VII by hageman factor fragments. Blood 1977; 50: 611-7.
11. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983; 71: 1450-6.
12. Toosi Z, Sedor JR, Mettler MA, Everson B, Young T, Ratnoff OD. Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Proc Natl Acad Sci U S A 1992; 89: 11969-72.
13. Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M, Colman RW. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986; 67: 1731-7.
14. Wachtfogel YT, Kettner C, Hack CE, Nuijens JH, Reilly TM, Knabb RM, Kucich U, Niewiarowski S, Edmunds LH Jr, Colman RW. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation. Thromb Haemost 1998; 80: 686-91.
15. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 2103-6.
16. Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, Miller GJ. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-62.
17. Cooper JA, Miller GJ, Bauer KA, Morrissey JH, Meade TW, Howarth DJ, Barzegar S, Mitchell JP, Rosenberg RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-22.
18. Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction: Association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79: 14-8.
19. Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 2004; 147: 260-6.
20. Bach J, Endler G, Winkelmann BO, Boehm W, Maerz C, Mannhalter P, Hellstern P. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C 46T gene polymorphism and coronary risk. J Thromb Haemost 2008; 6: 291-6.
21. Govers-Riemslag JW, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, Hamulyak K, Spronk HM, Miller GJ, Ten CateH. The plasma kallikrein.kinin system and risk of cardiovascular disease in men. J Thromb Haemost 2007; 5: 1896-903.
22. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-51.
23. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between Factor XII activity and overall survival. J Thromb Haemost 2007; 5: 1143-8.
24. Fujikawa K, Mc Mullen BA. Amino acid sequence of human beta-factor XIIa. J Biol Chem 1983; 258: 10924-33.
25. Mc Mullen BA, Fujikawa K. Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor). J Biol Chem 1985; 260: 5328-41.
26. Pönitz V, Pritchard D, Grundt H, Nilsen DW. Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase. J Thromb Thrombolysis 2006; 22: 199-203.
27. Pönitz V, Pritchard D, Grundt H, Mehus MB, Nilsen DW. Changes of plasma activated Factor XII type A (XIIaA) concentrations following percutaneous coronary intervention (PCI). J Thromb Thrombolysis 2007; 24: 131-5.
28. Esnouf MP, Burgess AI, Dodds AW, Sarphie AF, Miller GJ. A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not Factor XII or complexes of Factor XIIa with C1 esterase inhibitor. Thromb Haemost 2000; 83: 874-81.
29. Müller-Bardorff M, Hallermayer K, Schröder A, Ebert C, Borgya A, Gerhardt W, Remppis A, Zehelein J, Katus HA. Improved troponinT ELISA specific for cardiac troponinT isoform: Assay development and analytical and clinical validation. Clin Chem 1997; 43: 458-66.
30. Rawlins ML, Qwen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005; 123: 439-45.
31. Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, Rifai N. Evaluation of nine high-sensitivity C-reactive protein methods. Clin Chem 2001; 47: 418-25.
32. Zeerleder S, Schloesser M, Redondo M, Wuillemin WA, Engel W, Furlan M, Lammle B. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency -a study on 73 subjects from 13 Swiss families. Thromb Hemost 1999; 82: 1240-6.
33. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-81.
34. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-8.
35. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 2507-13.
36. Schousboe I. Pharmacological regulation of factor XII activation may be a target to control pathological coagulation. Biochem Pharmacol 2008; 75: 1007-13.
37. Müller F, Renne T. Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 2008; 15: 516-21.
38. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrisey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-8.
39. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Günther A, Engelmann B, Preissner KT. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007; 104: 6388-93.
40. Maas C, Govers-Riemslag JW, Bouma B, Schicks B, Hazenberg BP, Lokhorst HM, Hammarström P, ten Cate H, de Groot PG, Bouma BN, Gebbink MF. Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208-18.